Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOAS: Evolocumab for Progression of Moderate Aortic Stenosis
jRCTs031240618Recruiting
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of evolocumab in aortic stenosis (AS) and dyslipidemia (2 arms). Primary endpoint: Change in maximum aortic valve pressure gradient at 12 months. Started Feb 2025; status: recruiting.
02
Drugs
evolocumab
03
Conditions
aortic stenosis (AS)dyslipidemia
Beyond the preview
Go deeper on jRCTs031240618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240618.